Dr Jhaveri on RLY-2608 in PIK3CA-Mutant Advanced Breast Cancer
April 27th 2023Komal Jhaveri, MD, FACP, discusses findings from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial (NCT05216432) of the PI3Kα inhibitor RLY-2608 in patients with PIK3CA-mutant advanced breast cancer.
RLY-2608 Shows Broad Therapeutic Potential in PIK3CA-Mutant Solid Tumors
April 19th 2023RLY-2608 led to sustained target inhibition with minimal effect on glucose homeostasis, acceptable safety, and antitumor activity in patients with PIK3CA-mutant solid tumors, according to interim data from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial.